EDITAS MEDICINE INC.

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

25 أبريل 2024 09:45:02 بحسب NetDania Notify

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

24 أبريل 2024 15:42:20 بحسب NetDania Notify

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

22 أبريل 2024 16:31:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

19 أبريل 2024 09:45:22 بحسب NetDania Notify

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

18 أبريل 2024 09:45:09 بحسب NetDania Notify

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

17 أبريل 2024 09:45:46 بحسب NetDania Notify

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

16 أبريل 2024 09:45:13 بحسب NetDania Notify

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

15 أبريل 2024 10:47:30 بحسب NetDania Notify

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

28 فبراير 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

21 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

31 يناير 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

08 يناير 2024 08:15:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

13 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

11 ديسمبر 2023 12:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

03 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

02 نوفمبر 2023 09:12:24 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

27 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

16 أكتوبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

25 سبتمبر 2023 16:30:00 بحسب Nasdaq GlobeNewswire